@article{article, title = {{Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model}}, url = {{http://eprints.whiterose.ac.uk/100350/ }}, year = {{2016}}, month = {{5}}, author = {{Archer R and Tappenden P and Ren S and Martyn-St James M and Harvey R and Basarir H and Stevens J and Carroll C and Cantrell A and Lobo A and Hoque S}}, doi = {{10.3310/hta20390}}, volume = {{20}}, journal = {{Health Technology Assessment}}, issue = {{39}}, pages = {{1-326}}, note = {{Accessed on 2025/04/10}}}